Clinical Trial

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 13, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy
Trial Details
NCT Number NCT07019181
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Esophagus Cancer
Enrollment 26 participants
Start Date 2025-07-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-13